$2.24
Today
as of Sep 4, 16:51 ET
Last 30 days
Recent Press Releases & News
Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences
Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure
LXRX Stock Edges Higher On $10M Payout From Novo Nordisk — Retail Traders Highlight More Cash Milestones On The Horizon
Overview
52-week range
$1.05
$2.68
73% of range
Avg surprise (last 3)
+80.8%
Avg reaction (last 2)
-0.5%
50% positive
Latest IV / EM
171%
EM ±26.8% · $2 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.07 | — | — | — | — | financials |
| Thu May 7, 2026 | Mar/2026 | — | $-0.04 | +100.0% | +100.0% | +5.0% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.04 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $0.01 | $-0.08 | +112.5% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $-0.07 | $-0.10 | +30.0% | — | -6.0% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.18 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.17 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.20 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.21 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.22 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.17 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $692,000 | $21M | — | $14M | $29M | $1M | — | $2M |
| Cost of revenue | $39,000 | $108,000 | — | $10,000 | $33,000 | $30,000 | — | $71,000 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-27M | $-996,000 | — | $-12M | $4M | $-26M | — | $-64M |
| Net income | $-32M | $-1M | — | $-13M | $3M | $-25M | — | $-65M |
| EPS (diluted) | $-0.07 | — | — | $-0.04 | $0.01 | $-0.07 | — | $-0.18 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $41M | $38M | $34M | $50M | $21M | $63M | $67M | $35M |
| Inventory | $1M | $276,000 | $281,000 | $158,000 | $168,000 | $201,000 | $231,000 | $636,000 |
| Total current assets | $197M | $186M | $102M | $123M | $145M | $246M | $246M | $269M |
| Total assets | $250M | $269M | $185M | $206M | $226M | $298M | $298M | $321M |
| Long-term debt | $51M | $50M | $49M | $57M | $56M | $59M | $100M | $100M |
| Total liabilities | $76M | $66M | $77M | $86M | $96M | $175M | $152M | $143M |
| Total equity | $175M | $203M | $108M | $120M | $129M | $123M | $146M | $179M |